Generic Name and Formulations:
Metipranolol HCl 0.3%; oph soln; contains benzalkonium chloride.
Valeant Pharmaceuticals, Inc
Indications for OPTIPRANOLOL:
1 drop twice daily.
History of, or active, bronchial asthma. Severe COPD. Sinus bradycardia. Greater than 1st-degree AV block. Cardiogenic shock. Overt cardiac failure.
Not for use as sole agent in angle-closure glaucoma. History of cardiac failure. Discontinue at first sign of cardiac failure. Cerebrovascular insufficiency. Withdraw gradually before elective surgery. Diabetes. Hyperthyroidism. Myasthenia gravis. History of anaphylaxis. Pregnancy (Cat.C). Nursing mothers.
May potentiate systemic β-blockers, reserpine. Avoid concomitant calcium channel blockers in impaired cardiac function. Caution with adrenergic psychotropics.
Local discomfort. Rarely: conjunctivitis, eyelid dermatitis, blepharitis, blurred vision, tearing, browache, abnormal vision, photophobia, edema. Systemic absorption: bronchospasm, bradycardia, cardiac failure, depression, other β-blocker effects.
Endocrinology Advisor Articles
- Relationship Between HbA1c and Coronary Artery Disease
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Cushing Syndrome Results in Poor Quality of Life Even After Remission
- Cost-Benefit Analysis of Insulin Analogs in Type 2 Diabetes
- Nonfunctioning Adrenal Incidentaloma Associated With Metabolic Syndrome
- Low Predictive Power of Biomarkers for Estimated Glomerular Filtration Rate Decline
- FDA to Review Gimoti for Diabetic Gastroparesis in Adult Women
- FDA Approves First Mobile App for Use in Preventing Pregnancy
- Hypothyroidism Predicts Atrial Tachyarrhythmia After AF Catheter Ablation
- Treating Painful Diabetic Peripheral Neuropathy With Electroacupuncture